Prism MarketView

March 25, 2024 at 2:23 pm

Seelos Misses Endpoints in Blow to ALS Community

Biopharmaceutical company, Seelos Therapeutics (Nasdaq: SEEL) has missed primary and secondary endpoints in its Phase 2/3 HEALEY ALS Platform trial of SLS-005 in a blow… [Read More]

March 25, 2024 at 8:52 am

BrainsWay Receives Significant New Order for Deep TMS™ Systems

Mental health company, BrainsWay Ltd. (Nasdaq: BWAY) has received an order for 18 of its Deep Transcranial Magnetic Stimulation (Deep TMS™) systems from Katie’s Way… [Read More]

March 22, 2024 at 9:52 am

Rare Pediatric Disease Designation for Lisata’s Osteosarcoma Candidate

Lisata Therapeutics (Nasdaq: LSTA) has been granted Rare Pediatric Disease Designation by the FDA for LSTA1, the company’s lead product candidate, for the treatment of… [Read More]

March 22, 2024 at 8:37 am

Cybin Closes $150M Private Placement; New Capital to Support Phase 3 Drug Development

Next-generation psychedelics company, Cybin, Inc (NYSE American: CYBN) has closed an oversubscribed private placement of 348,837,210 common shares at a price of $0.43 per share,… [Read More]

March 21, 2024 at 1:12 pm

Bionomics Candidate Offers Hope for 13 Million Americans Living with Post-Traumatic Stress

Clinical-stage biotechnology company, Bionomics Limited (Nasdaq: BNOX), is offering hope to the more than 13 million Americans living with post-traumatic stress disorder (PTSD), a debilitating… [Read More]

March 21, 2024 at 8:48 am

Enveric Biosciences Outlicenses Compounds Generated by AI Drug Discovery System

Enveric Biosciences (Nasdaq: ENVB) has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds. The… [Read More]

March 20, 2024 at 4:51 pm

Clearmind to Commence Clinical Trial in Alcohol-Use Disorder

Psychedelic drug company, Clearmind Medicine Inc. (Nasdaq: CMND), has received approval from the Israeli Ministry of Health to commence its Phase 1/2a clinical trial for… [Read More]

March 19, 2024 at 11:12 am

ZyVersa Therapeutics Offers Hope to 32 Million Americans Living with Kidney Disease

Clinical stage biopharmaceutical company, ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), has received Institutional Review Board (IRB) approval of its Phase 2a clinical trial protocol to evaluate… [Read More]

March 19, 2024 at 9:33 am

Marvel Biosciences Reports Promising Preclinical Results from Autism Study

Marvel Biosciences Corp. (OTCQB: MBCOF) has reported promising interim results from its study on MB-204, a new treatment for autism. The study, being conducted by… [Read More]

March 18, 2024 at 3:50 pm

SciSparc Doses First Patient in Autism Treatment Trial

SciSparc Ltd. (Nasdaq: SPRC) has successfully dosed the first patient in its SCI-210 clinical trial for pediatric patients with Autism Spectrum Disorder (ASD). This is… [Read More]

March 18, 2024 at 2:47 pm

Fennec Pharmaceuticals to Commercialize Protective Treatment for Chemotherapy-Induced Hearing Loss

Shares in commercial stage pharmaceutical company, Fennec Pharmaceuticals Inc. (Nasdaq: FENC), rose 11% in morning trading on Monday after the company announced it will partner… [Read More]

March 15, 2024 at 2:43 pm

NeuroBo Secures Safety Review Committee Approval for MASH Treatment Trial

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has received Safety Review Committee (SRC) approvalrecommending that the company’s two-part Phase 2a trial of DA-1241, for the treatment of… [Read More]

Tag: BIO TECH